Page last updated: 2024-10-22

amsacrine and Acute Myelogenous Leukemia

amsacrine has been researched along with Acute Myelogenous Leukemia in 159 studies

Amsacrine: An aminoacridine derivative that intercalates into DNA and is used as an antineoplastic agent.
amsacrine : A sulfonamide that is N-phenylmethanesulfonamide substituted by a methoxy group at position 3 and an acridin-9-ylamino group at position 4. It exhibits antineoplastic activity.

Research Excerpts

ExcerptRelevanceReference
"Amsacrine and high-dose cytarabine (HiDAc), when administered as single agents, are effective treatment of acute leukemia."9.06A new regimen of amsacrine with high-dose cytarabine is safe and effective therapy for acute leukemia. ( Ahmed, T; Arlin, ZA; Baskind, P; Feldman, E; Mehta, R; Mittelman, A; Rieber, E; Sullivan, P; Weinstein, P, 1987)
"Patients with acute myelogenous leukemia in relapse who were ineligible for further anthracycline therapy either because they were judged to be anthracycline resistant or had received the maximum doses were randomized to receive high-dose cytarabine (3 g/m2 every 12 hours for 6 days) or amsacrine (75 mg/m2 daily for 7 days)."9.06Randomized trial of high-dose cytarabine versus amsacrine in acute myelogenous leukemia in relapse: a Leukemia Intergroup Study. ( Brennan, J; Browman, G; Goldberg, J; Gottlieb, AJ; Grunwald, H; Miller, KB; Preisler, HD; Rai, K; Vogler, WR; Winton, EF, 1986)
"The role of amsacrine in inducing remission in patients with cardiac disease and acute leukemia was evaluated."7.68Amsacrine is safe and effective therapy for patients with myocardial dysfunction and acute leukemia. ( Ahmed, T; Arlin, ZA; Baskind, P; Chun, HG; Cook, P; Feldman, EJ; Marboe, C; Mehta, R; Mittelman, A; Puccio, C, 1991)
"We describe 2 patients in whom a sustained remission of longstanding rheumatoid arthritis occurred with treatment for acute myelogenous leukemia (cytosine arabinoside, daunorubicin, and m-AMSA), even though both illnesses had been refractory to therapy with standard disease-modifying agents."7.67Remission of rheumatoid arthritis with the successful treatment of acute myelogenous leukemia with cytosine arabinoside, daunorubicin, and m-AMSA. ( Jones, RJ; Karp, JE; Roubenoff, R; Stevens, MB, 1987)
"Twenty-six adults with refractory leukemia were treated with amsacrine gluconate, a new formulation."7.66Phase II study of amsacrine gluconate in refractory leukemia. ( Grillo-Lopez, AJ; Omura, GA; Vogler, WR; Winton, EF; Zuckerman, KS, 1983)
" In acute myelogenous leukemia, amsacrine is as effective as the two most active drugs, cytarabine and daunorubicin and can produce complete remissions in patients refractory to these drugs."6.15Amsacrine: a review. ( Cassileth, PA; Gale, RP, 1986)
"Amsacrine was also found to be highly bound to plasma proteins (96."5.27Pharmacokinetics of amsacrine in patients receiving combined chemotherapy for treatment of acute myelogenous leukemia. ( Jurlina, JL; Paxton, JW; Varcoe, AR, 1985)
"Forty-eight patients with acute myelogenous leukemia (AML) not eligible for anthracycline or mitoxantrone treatment, mostly due to cardiac contraindications, were given aggressive therapy using m-amsacrine (AMSA) in combination with conventional or high-dose cytarabine for remission induction."5.07AMSA combination chemotherapy in patients with acute myelogenous leukemia unsuitable for standard antileukemic treatment. ( Heit, W; Maschmeyer, G; Willborn, K, 1992)
"In a randomized trial, 299 evaluable patients with acute myelogenous leukemia, age greater than or equal to 51, were initially randomized to cytosine arabinoside, 100 mg/m2/day, by continuous intravenous infusion for seven days, plus either daunorubicin 45 mg/m2/day x 3 (DA), or m-AMSA 200 mg/m2/day x 3 days (MA)."5.06Therapy of acute myelogenous leukemia in patients over the age of 50: a randomized Southeastern Cancer Study Group trial. ( Bartolucci, A; Cohen, HJ; Raney, MR; Stein, RS; Vogler, WR; Winton, EF, 1990)
"Amsacrine and high-dose cytarabine (HiDAc), when administered as single agents, are effective treatment of acute leukemia."5.06A new regimen of amsacrine with high-dose cytarabine is safe and effective therapy for acute leukemia. ( Ahmed, T; Arlin, ZA; Baskind, P; Feldman, E; Mehta, R; Mittelman, A; Rieber, E; Sullivan, P; Weinstein, P, 1987)
"Patients with acute myelogenous leukemia in relapse who were ineligible for further anthracycline therapy either because they were judged to be anthracycline resistant or had received the maximum doses were randomized to receive high-dose cytarabine (3 g/m2 every 12 hours for 6 days) or amsacrine (75 mg/m2 daily for 7 days)."5.06Randomized trial of high-dose cytarabine versus amsacrine in acute myelogenous leukemia in relapse: a Leukemia Intergroup Study. ( Brennan, J; Browman, G; Goldberg, J; Gottlieb, AJ; Grunwald, H; Miller, KB; Preisler, HD; Rai, K; Vogler, WR; Winton, EF, 1986)
"Bortezomib, a proteasome inhibitor, has been used for patients with refractory and relapsed multiple myeloma, lymphoma and leukemia."3.74The high incidence of varicella herpes zoster with the use of bortezomib in 10 patients. ( Jin, J; Li, Y; Meng, H; Qian, J; Tong, Y, 2007)
"The topoisomerase (topo) II-directed agents etoposide, daunorubicin (DNR), and amsacrine (m-AMSA) are widely used in the treatment of acute myelogenous leukemia (AML)."3.69Topoisomerase II levels and drug sensitivity in adult acute myelogenous leukemia. ( Burke, PJ; Cowan, K; Jones, RJ; Karp, JE; Kaufmann, SH; Miller, CB; Schneider, E; Wendel, K; Zwelling, LA, 1994)
"The role of amsacrine in inducing remission in patients with cardiac disease and acute leukemia was evaluated."3.68Amsacrine is safe and effective therapy for patients with myocardial dysfunction and acute leukemia. ( Ahmed, T; Arlin, ZA; Baskind, P; Chun, HG; Cook, P; Feldman, EJ; Marboe, C; Mehta, R; Mittelman, A; Puccio, C, 1991)
" The overall complete remission rate was 27/78 (35%) in acute myelogenous leukemia and 5/9 (56%) in acute lymphocytic leukemia or acute undifferentiated leukemia for cytosine arabinoside combined with either anthracyclines (rubidazone or Adriamycin [doxorubicin]) or m-AMSA (amsacrine)."3.67Intensive treatment of acute leukemia in adults 70 years of age and older. ( Estey, EH; Freireich, EJ; Kantarjian, HM; Keating, MJ; McCredie, KB; Walters, RS, 1987)
"We describe 2 patients in whom a sustained remission of longstanding rheumatoid arthritis occurred with treatment for acute myelogenous leukemia (cytosine arabinoside, daunorubicin, and m-AMSA), even though both illnesses had been refractory to therapy with standard disease-modifying agents."3.67Remission of rheumatoid arthritis with the successful treatment of acute myelogenous leukemia with cytosine arabinoside, daunorubicin, and m-AMSA. ( Jones, RJ; Karp, JE; Roubenoff, R; Stevens, MB, 1987)
"Twenty-six adults with refractory leukemia were treated with amsacrine gluconate, a new formulation."3.66Phase II study of amsacrine gluconate in refractory leukemia. ( Grillo-Lopez, AJ; Omura, GA; Vogler, WR; Winton, EF; Zuckerman, KS, 1983)
"Strategies to reduce recurrence are urgently required."3.01Augmented Reduced-Intensity Regimen Does Not Improve Postallogeneic Transplant Outcomes in Acute Myeloid Leukemia. ( Andrew, G; Byrne, J; Craddock, C; Crawley, C; Dillon, R; Freeman, SD; Gilleece, M; Hodgkinson, A; Hunter, A; Jackson, A; Khan, N; Loke, J; Malladi, R; Mason, J; McCarthy, N; Nagra, S; Parker, A; Pavlu, J; Peniket, A; Potter, V; Protheroe, R; Salim, R; Siddique, S; Tholouli, E; Vyas, P; Wheatley, K; Wilson, K, 2021)
"Patients with acute myeloid leukemia (AML) in first relapse after initial Complete Remission (CR) lasting ≥1 month were stratified per the European Prognostic Index (EPI) into favorable, intermediate, and poor-risk groups based on duration of first CR, cytogenetics, age, and transplant history."2.80Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML. ( Cortes, JE; Feldman, EJ; Goldberg, SL; Hogge, DE; Kantarjian, H; Kolitz, JE; Larson, M; Louie, AC; Pigneux, A; Recher, C; Rizzeri, DA; Schiller, G; Warzocha, K, 2015)
"We treated 305 de novo acute myeloid leukemia (AML) patients aged 2.71Risk-adapted induction and consolidation therapy in adults with de novo AML aged Arnold, R; Bergmann, L; Fiedler, W; Ganser, A; Heil, G; Hoelzer, D; Kirchner, H; Krauter, J; Lübbert, M; Noens, L; Raghavachar, A; Schlimok, G, 2004)
"Twenty-nine patients with acute myeloid leukemia (AML) received a salvage therapy of amsacrine plus IDAC and etoposide, while 22 patients with acute lymphoblastic leukemia (ALL) received amsacrine plus IDAC."2.71Phase II trial of amsacrine plus intermediate-dose Ara-C (IDAC) with or without etoposide as salvage therapy for refractory or relapsed acute leukemia. ( Ahn, BM; Baek, JH; Jeon, SB; Kim, DH; Kim, JG; Lee, KB; Moon, JH; Sohn, SK; Sung, WJ, 2005)
"5-Aza-2'-deoxycytidine combined with either amsacrine or idarubicin has been applied in a treatment protocol for patients with a relapse of acute myeloid or lymphocytic leukemia."2.68A randomized phase II study on the effects of 5-Aza-2'-deoxycytidine combined with either amsacrine or idarubicin in patients with relapsed acute leukemia: an EORTC Leukemia Cooperative Group phase II study (06893). ( Archimbaud, E; Berneman, Z; Dardenne, M; Dohner, H; Jaksic, B; Jehn, U; Labar, B; Louwagie, EA; Muus, P; Stryckmans, P; Suciu, S; Tjean, M; Wijermans, P; Willemze, R; Zittoun, R, 1997)
" An additional 17 patients received those two agents plus azacitidine at a dosage of 250 mg/M2 on days 4 and 5."2.67Toxicity trials of amsacrine (AMSA) and etoposide +/- azacitidine (AZ) in childhood acute non-lymphocytic leukemia (ANLL): a pilot study. ( Camitta, B; Holbrook, T; Krischer, J; Land, VJ; Sexauer, C; Steuber, CP, 1991)
" Further investigation of this drug combination in untreated patients with ANLL is warranted."2.66Comparative trial of cytarabine and thioguanine in combination with amsacrine or daunorubicin in patients with untreated acute nonlymphocytic leukemia: results of the L-16M protocol. ( Andreeff, M; Arlin, ZA; Berman, E; Gaynor, J; Gee, T; Kempin, SJ; Mertelsmann, R; Miller, W; Nahmias, N; Reich, L, 1989)
"Since 1980, adults with acute myelocytic leukemia (AML) have been treated on two clinical studies using intensive timed sequential therapy."2.66A two-step timed sequential treatment for acute myelocytic leukemia. ( Braine, HG; Burke, PJ; Fox, MG; Geller, RB; Hall, KL; Humphrey, RL; Karp, JE; Morrell, L; Tucker, RW; Zahurak, M, 1989)
"Amsacrine is an effective replacement for daunorubicin in the treatment of APL, and its use does not compromise the favorable remission duration characteristic of APL."2.65Primary therapy of acute promyelocytic leukemia: results of amsacrine- and daunorubicin-based therapy. ( Arlin, Z; Chaganti, RS; Clarkson, B; Gee, T; Higgins, C; Jhanwar, S; Kempin, S; Mertelsmann, R, 1984)
"This first described case of toxic megacolon following leukaemia treatment is compared with three previously described cases following cytotoxic chemotherapy for other conditions."2.39Toxic megacolon complicating chemotherapy for acute myeloid leukaemia. ( Reilly, JT; Snowden, JA; Wodziński, MA, 1994)
"HDARAC is also active in acute lymphocytic leukemia."2.37High dose cytarabine: a review. ( Bolwell, BJ; Cassileth, PA; Gale, RP, 1988)
"FLAG-amsacrine was an effective bridge to allogeneic transplant with 38% successfully transplanted with excellent outcomes (median OS not reached)."1.39Fludarabine, cytarabine, granulocyte-colony stimulating factor and amsacrine: an effective salvage therapy option for acute myeloid leukemia at first relapse. ( Avery, S; Campbell, P; Coutsouvelis, J; Fong, CY; Grigoriadis, G; Hocking, J; Muirhead, J; Patil, S; Paul, E; Schwarer, A; Spencer, A; Walker, P; Wei, A, 2013)
"This trial determined that it is safe and feasible to include gemtuzumab ozogamicin in combination with intensive chemotherapy."1.38AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: a report from the Children's Oncology Group. ( Alonzo, TA; Arceci, RJ; Cooper, TM; Feusner, J; Franklin, J; Gamis, A; Gerbing, RB; Hirsch, B; Hurwitz, C; Iannone, R; Lavey, RS; Mathew, P; Meshinchi, S; Raimondi, SC; Smith, FO, 2012)
"The prognosis for DS acute myeloid leukemia (AML) is better than for non-DS AML, but the clinical outcome of DS acute lymphoblastic leukemia (ALL) is equal to that of non-DS ALL."1.31Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome. ( Creutzig, U; de Vries, E; Hählen, K; Huismans, DR; Janka-Schaub, GE; Jansen, G; Kaspers, GJ; Peters, GJ; Pieters, R; Rots, MG; van Zantwijk, CH; Veerman, AJ; Zwaan, CM, 2002)
" The intra-individual variation was much less, suggesting that dose adjustment based on pharmacokinetic data might be useful in the future."1.30In vitro cytotoxic drug activity and in vivo pharmacokinetics in childhood acute myeloid leukemia. ( Frost, BM; Larsson, R; Liliemark, E; Lönnerholm, G; Nygren, P; Peterson, C, 1999)
"Treatment-related acute myeloid leukemia (t-AML) following successful therapy of a primary malignancy has been recognized with increasing frequency among cancer survivors over the past several years."1.30Topoisomerase II inhibitors induce DNA double-strand breaks at a specific site within the AML1 locus. ( Aplan, PD; Chervinsky, DS; Stanulla, M; Wang, J, 1997)
"Ten patients with acute myeloblastic leukemia (AML) in first relapse were treated with high-dose cytosine-arabinoside (ara-C, 3 g/m2/12 hours x 4) and amsacrine (150 mg/m2/day x 5)."1.29Treatment of relapsed acute myeloid leukemia using GM-CSF before intensive chemotherapy. ( Belloc, F; Bernard, P; Boiron, JM; Cony-Makhoul, P; Dumain, P; Lacombe, F; Laurent, G; Marit, G; Puntous, M; Reiffers, J, 1993)
"Samples from 31 patients with acute myelocytic leukemia (AML) were tested with continuous drug exposure."1.29Interactions between cladribine (2-chlorodeoxyadenosine) and standard antileukemic drugs in primary cultures of human tumor cells from patients with acute myelocytic leukemia. ( Fridborg, H; Killander, A; Kristensen, J; Larsson, R; Liliemark, J; Nygren, P; Oberg, G; Simonsson, B, 1994)
"Twenty-one acute myelogenous leukemia (AML) patients were submitted in second remission (II CR) to BAVC conditioning regimen followed by unpurged ABMT."1.28BAVC regimen and autologous bone marrow transplantation in patients with acute myelogenous leukemia in second remission. ( De Fabritiis, P; Mandelli, F; Meloni, G; Petti, MC, 1990)
"Thus, the CR rate for relapsed ANLL patients who received the higher doses of both agents was 40% (13 of 33)."1.28Effective reinduction therapy for childhood acute nonlymphoid leukemia using simultaneous continuous infusions of teniposide and amsacrine. ( Dahl, GV; Grier, HE; Kalwinsky, DK; Mason, C; Mirro, J; Murphy, SB; Santana, VM, 1989)
"A case of necrotizing fasciitis of the vulva arising in a leukemic patient during a chemotherapy nadir is presented."1.28Necrotizing fasciitis of the vulva during chemotherapy. ( Hoffman, MS; Turnquist, D, 1989)
" Dosage was 75 mg/m2, iv, day 1-7, all 3-5 weeks."1.27[Phase II study of AMSA in adults with acute therapy-refractory leukemias]. ( Engelhardt, R; Fiebig, HH; Henss, H; Hoelzer, D; Link, H; Pralle, H; Schmitz, R, 1983)
" Resistance was not due to a decrease in the bioavailability of the drug."1.27Development and characterization of a human myelogenous leukemia cell line resistant to 4'-(9-acridinylamino)-3-methanesulfon-m-anisidide. ( Andersson, BS; Beran, M, 1987)
" The LD50 values observed in normal and leukemic Brown-Norway rats were 26."1.27AMSA: in vivo log cell kill for leukemic clonogenic cells versus toxicity for normal hemopoietic stem cells in a rat model for human acute myelocytic leukemia (BNML). ( Hagenbeek, A; Martens, AC, 1986)
"Five children treated for acute myeloid leukemia according to the BFM protocol AML 83 experienced first bone marrow relapse after 7, 10, 14, 18, and 30 months and were retreated for second remission induction."1.27Effective remission induction in children with recurrent acute myeloid leukemia by mAMSA, Ara-C, and VP 16. ( Berthold, F; Creutzig, U; Lampert, F, 1987)
"27 patients with resistant acute myelogenous leukemia (AML) were treated with AMSA."1.27AMSA: a phase II trial in resistant and recurrent acute myelogenous leukemia. ( Boccia, R; Champlin, RE; Gale, RP; Kim, CC; Zighelboim, J, 1984)
"Amsacrine, 90 mg/m2, was given daily for 5-8 days to 45 patients with acute myeloblastic leukemia, 15 patients with acute lymphoblastic leukemia, and six patients with blastic transformation of chronic granulocytic leukemia."1.27Amsacrine in refractory adult acute leukemia: a pilot study of the Southeastern Cancer Study Group. ( Hearn, EB; Johnson, L; Logan, T; Raney, M; Vogler, WR; Winton, EF, 1983)
"Etoposide was administered on days 1 and 5 with a constant loading dose of 100 mg/m2 by an 1-h infusion followed by a 23-h infusion, the dose of which was escalated in 3 steps from 110 mg/m2 to 200 mg/m2 and 230 mg/m2."1.27[Combined therapy with AMSA and etoposide (VP 16-213) in refractory acute myeloid leukemia. A phase I study]. ( Achterrath, W; Balleisen, L; Büchner, T; Hiddemann, W; Kirchhof, B; Preusser, P; Stenzinger, W; Urbanitz, D, 1984)
"Amsacrine was also found to be highly bound to plasma proteins (96."1.27Pharmacokinetics of amsacrine in patients receiving combined chemotherapy for treatment of acute myelogenous leukemia. ( Jurlina, JL; Paxton, JW; Varcoe, AR, 1985)

Research

Studies (159)

TimeframeStudies, this research(%)All Research%
pre-199078 (49.06)18.7374
1990's56 (35.22)18.2507
2000's11 (6.92)29.6817
2010's11 (6.92)24.3611
2020's3 (1.89)2.80

Authors

AuthorsStudies
Meur, GL1
Plesa, A1
Larcher, MV1
Fossard, G1
Barraco, F1
Loron, S1
Balsat, M1
Ducastelle-Leprêtre, S1
Gilis, L1
Thomas, X1
Ghesquières, H1
Tigaud, I1
Hayette, S1
Huet, S1
Sujobert, P1
Renault, M1
Thérèse, RM1
Michallet, M2
Labussière-Wallet, H1
Heiblig, M1
Kuron, D1
Pohlmann, A1
Angenendt, L1
Kessler, T2
Mesters, R1
Berdel, WE3
Stelljes, M1
Lenz, G1
Schliemann, C2
Mikesch, JH1
Craddock, C1
Jackson, A1
Loke, J1
Siddique, S1
Hodgkinson, A1
Mason, J1
Andrew, G1
Nagra, S1
Malladi, R1
Peniket, A1
Gilleece, M1
Salim, R1
Tholouli, E1
Potter, V1
Crawley, C1
Wheatley, K1
Protheroe, R1
Vyas, P1
Hunter, A1
Parker, A1
Wilson, K1
Pavlu, J1
Byrne, J1
Dillon, R1
Khan, N1
McCarthy, N1
Freeman, SD1
Schaich, M1
Parmentier, S1
Kramer, M1
Illmer, T1
Stölzel, F1
Röllig, C1
Thiede, C1
Hänel, M1
Schäfer-Eckart, K1
Aulitzky, W1
Einsele, H1
Ho, AD1
Serve, H2
Mayer, J2
Schmitz, N1
Krause, SW1
Neubauer, A2
Baldus, CD1
Schetelig, J1
Bornhäuser, M1
Ehninger, G1
Krejci, M1
Doubek, M1
Dusek, J1
Brychtova, Y1
Racil, Z1
Navratil, M1
Tomiska, M1
Horky, O1
Pospisilova, S1
Feliu, J1
Clay, J1
Raj, K1
Barber, L1
Devlia, V1
Shaw, B1
Pagliuca, A1
Mufti, G1
Cortes, JE1
Goldberg, SL1
Feldman, EJ2
Rizzeri, DA1
Hogge, DE1
Larson, M1
Pigneux, A1
Recher, C1
Schiller, G1
Warzocha, K1
Kantarjian, H2
Louie, AC1
Kolitz, JE1
Pfrepper, C1
Klink, A1
Behre, G1
Schenk, T1
Franke, GN1
Jentzsch, M1
Schwind, S1
Al-Ali, HK1
Hochhaus, A1
Niederwieser, D1
Sayer, HG1
Malard, F1
Labopin, M3
Stuhler, G1
Bittenbring, J1
Ganser, A2
Tischer, J3
Kröger, N1
Schmid, C3
Huynh, A1
Hallek, M1
Savani, BN1
Mohty, M1
Nagler, A1
Schleuning, M2
Holler, E1
Haude, KH1
Braess, J1
Haferlach, C1
Baurmann, H1
Oruzio, D1
Hahn, J1
Spiekermann, K1
Schlimok, G2
Schwerdtfeger, R1
Buechner, T1
Hiddemann, W3
Kolb, HJ2
Wilhelm, C1
Burchert, A1
Cooper, TM1
Franklin, J1
Gerbing, RB1
Alonzo, TA1
Hurwitz, C1
Raimondi, SC1
Hirsch, B1
Smith, FO1
Mathew, P1
Arceci, RJ1
Feusner, J1
Iannone, R1
Lavey, RS1
Meshinchi, S1
Gamis, A1
Saure, C1
Schroeder, T1
Zohren, F1
Groten, A1
Bruns, I1
Czibere, A1
Galonska, L1
Kondakci, M1
Weigelt, C1
Fenk, R1
Germing, U1
Haas, R1
Kobbe, G1
Fong, CY1
Grigoriadis, G1
Hocking, J1
Coutsouvelis, J1
Muirhead, J1
Campbell, P1
Paul, E1
Walker, P1
Avery, S1
Patil, S1
Spencer, A1
Schwarer, A1
Wei, A1
Locatelli, F1
Ortega, J1
Meloni, G8
Dini, G1
Messina, C1
Yaniv, I1
Fagioli, F1
Castel, V1
Shaw, PJ1
Ferrant, A2
Pession, A1
Sociè, G1
Frassoni, F2
Fouillard, L1
Polge, E1
Gorin, NC1
Heil, G1
Krauter, J1
Raghavachar, A1
Bergmann, L1
Hoelzer, D2
Fiedler, W1
Lübbert, M1
Noens, L1
Arnold, R1
Kirchner, H1
Ledderose, G1
Boutonnat, J1
Faussat, AM1
Marie, JP6
Bignon, J1
Wdzieczak-Bakala, J1
Barbier, M1
Thierry, J1
Ronot, X1
Colle, PE1
Sung, WJ1
Kim, DH1
Sohn, SK1
Kim, JG1
Baek, JH1
Jeon, SB1
Moon, JH1
Ahn, BM1
Lee, KB1
Tong, Y1
Qian, J1
Li, Y1
Meng, H1
Jin, J1
Mohr, M1
Müller-Tidow, C1
Krug, U1
Brunnberg, U1
Mohr, B1
Sauerland, C1
Büchner, T3
Mesters, RM1
Weidenaar, AC1
de Jonge, HJ1
Fidler, V1
ter Elst, A1
Meeuwsen-de Boer, T1
Douwes, J1
Bouma-ter Steege, JC1
Hählen, K2
Kamps, WA1
de Bont, ES1
Cabanillas, F1
Obrecht, JP1
Fiebig, HH1
Henss, H1
Engelhardt, R1
Pralle, H1
Link, H1
Schmitz, R1
Achterrath, W2
Urbanitz, D2
Preusser, P2
Balleisen, L2
Kirchhof, B1
Stenzinger, W1
Hittelman, WN1
Menegaz, SD1
McCredie, KB10
Keating, MJ11
Nagura, E1
Kawashima, K1
Suzuki, H1
Ohno, R1
Yamada, K1
Yokomaku, S1
Ogawa, M2
Winton, EF4
Hearn, EB1
Vogler, WR4
Johnson, L1
Logan, T1
Raney, M1
Arlin, Z1
Kempin, S1
Mertelsmann, R2
Gee, T2
Higgins, C1
Jhanwar, S1
Chaganti, RS1
Clarkson, B1
Omura, GA2
Zuckerman, KS1
Grillo-Lopez, AJ1
Estey, EH7
Smith, TL2
Legha, SS3
Walters, RS3
Bodey, GP3
Freireich, EJ12
Boccia, R1
Zighelboim, J1
Champlin, RE2
Kim, CC1
Gale, RP3
Case, DC1
Epstein, J1
Preisler, HD2
Weil, M1
Auclerc, MF1
Schaison, G3
Auclerc, G1
Daubrisson, A1
Degos, L1
Caro, J1
Marty, M2
Jacquillat, GI1
Zander, AR2
Issell, BF1
Buick, RN1
Chang, LJ1
Messner, HA1
Curtis, JE1
McCulloch, EA1
Slevin, ML1
Shannon, MS2
Prentice, HG3
Goldman, AJ1
Lister, TA3
Goldman, A1
Malpas, JS2
Lawrence, HJ1
Ries, CA1
Reynolds, RD1
Lewis, JP1
Koretz, MM1
Torti, FM1
Dupont, JC1
Garay, GE1
Scaghone, C1
Pavlovsky, S1
Woodley, PV1
Volger, WR1
Weiner, RS1
Moore, JO1
Bartolucci, AA1
Stagg, M1
Zittoun, RA1
Mandelli, F8
Willemze, R10
de Witte, T3
Labar, B2
Resegotti, L1
Leoni, F1
Damasio, E1
Visani, G1
Papa, G1
Wodziński, MA1
Snowden, JA1
Reilly, JT1
Kaufmann, SH1
Karp, JE3
Jones, RJ2
Miller, CB1
Schneider, E1
Zwelling, LA4
Cowan, K1
Wendel, K1
Burke, PJ2
Kristensen, J1
Nygren, P2
Liliemark, J1
Fridborg, H1
Killander, A2
Simonsson, B1
Oberg, G1
Larsson, R2
Ghaddar, HM1
Plunkett, W3
Kantarjian, HM4
Pierce, S1
Puntous, M1
Lacombe, F1
Dumain, P1
Marit, G3
Cony-Makhoul, P1
Belloc, F1
Boiron, JM2
Laurent, G1
Bernard, P2
Reiffers, J3
Daenen, S1
Löwenberg, B5
Sonneveld, P1
van Putten, WL1
Verhoef, G1
Verdonck, LF2
van Veldhoven, M1
Huijgens, PC2
Delmer, A2
Thevenin, D2
Suberville, AM3
Zittoun, R12
Jehn, U10
Heinemann, V2
Rio, B2
Vekhof, A1
Tura, S1
Ferrini, PR1
Stryckmans, P4
Steuber, CP2
Krischer, J2
Holbrook, T2
Camitta, B2
Land, V1
Sexauer, C2
Mahoney, D1
Weinstein, H1
Hardegger, TP1
von Rohr, A1
Tobler, A1
Fey, MF1
Vignetti, M2
Avvisati, G1
Capria, S1
Micozzi, A1
Giona, F1
Stanulla, M1
Wang, J1
Chervinsky, DS1
Aplan, PD1
Suciu, S3
Archimbaud, E1
Muus, P2
Louwagie, EA1
Berneman, Z1
Tjean, M1
Wijermans, P1
Dohner, H1
Jaksic, B1
Dardenne, M1
Sundström, GM1
Wahlin, A2
Elonen, E1
Almqvist, A1
Hänninen, A1
Jansson, SE1
Järventie, G1
Koistinen, P1
Koivunen, E1
Lahtinen, R1
Lehtinen, M1
Nousiainen, T1
Pelliniemi, TT1
Rajamäki, A1
Remes, K1
Timonen, T1
Vilpo, J1
Volin, L1
Ruutu, T1
Beksaç, M1
Arslan, O1
Koç, H1
Akan, H1
Ilhan, O1
Arat, M1
Ozcan, M1
Gürman, G1
Konuk, N1
Uysal, A1
Möllgård, L1
Tidefelt, U2
Sundman-Engberg, B1
Löfgren, C1
Lehman, S1
Paul, C2
Lönnerholm, G1
Frost, BM1
Liliemark, E1
Peterson, C1
Zwaan, CM1
Kaspers, GJ1
Pieters, R1
Janka-Schaub, GE1
van Zantwijk, CH1
Huismans, DR1
de Vries, E1
Rots, MG1
Peters, GJ1
Jansen, G1
Creutzig, U2
Veerman, AJ1
Perel, Y1
Auvrignon, A1
Leblanc, T1
Vannier, JP1
Michel, G1
Nelken, B1
Gandemer, V1
Schmitt, C1
Lamagnere, JP1
De Lumley, L1
Bader-Meunier, B1
Couillaud, G1
Landman-Parker, J1
Thuret, I1
Dalle, JH1
Baruchel, A1
Leverger, G2
Maschmeyer, G1
Willborn, K1
Heit, W1
Legrand, O1
Russo, D1
Zhou, D1
Hurwitz, CA1
Krance, R1
Schell, MJ1
Santana, VM2
Brenner, MK1
Ribeirio, R1
Roberts, WM1
Mahmoud, H1
Belt, J1
Crom, W1
Evensen, SA1
Brinch, L1
Stavem, P1
Tjønnfjord, G1
Hansz, J1
Bajko, G1
Woźny, T1
Drozdowska, D1
Berman, E2
Estey, E2
O'Brien, S1
Koller, C1
Beran, M5
Gahrton, G1
Björkholm, M1
Grimfors, G1
Hast, R1
Juliusson, G1
Järnmark, M1
Kimby, E1
Spinolo, JA1
Dicke, KA1
Horwitz, LJ1
Jagannath, S1
Auber, ML1
Spitzer, G1
Rees, JK3
Gray, RG1
Fiere, D2
Haanen, C4
Peetermans, M2
Solbu, G2
Miller, LP1
Pyesmany, AF1
Wolff, LJ1
Rogers, PC1
Siegel, SE1
Wells, RJ1
Buckley, JD1
Hammond, GD1
Land, VJ1
Ortega Aramburu, JJ1
Olivé Oliveras, T1
Javier Manchón, G1
Bastida Vila, P1
Sánchez, C1
Giralt López, J1
Arlin, ZA5
Mittelman, A2
Ahmed, T2
Puccio, C1
Chun, HG1
Cook, P1
Baskind, P2
Marboe, C1
Mehta, R2
De Fabritiis, P4
Petti, MC4
Pinto, MR1
Testi, AM1
Vegna, ML1
Bach, F1
Videbaek, C1
Holst-Christensen, J1
Boesby, S1
Limonta, M1
Ubezio, P1
Catapano, CV1
Conter, V1
Costato, C1
Masera, G1
Specchia, G1
Liso, V1
Barbui, T1
Giudici, G1
Petros, WP1
Rodman, JH1
Mirro, J2
Evans, WE1
Hansen, OP1
Pedersen-Bjergaard, J1
Ellegaard, J1
Brincker, H1
Boesen, AM1
Christensen, BE1
Drivsholm, A1
Hippe, E1
Jans, H1
Jensen, KB1
Cassileth, PA3
Harrington, DP1
Hines, JD1
Oken, MM1
Mazza, JJ1
McGlave, P1
Bennett, JM1
Lynch, E1
O'Connell, MJ1
Martiat, P1
Ghilain, JM1
Doyen, C1
Delannoy, A1
Chatelain, C1
Bosly, A1
Michaux, JL1
Sokal, G1
Stein, RS1
Cohen, HJ1
Raney, MR1
Bartolucci, A1
Skinner, WL1
Murray, D1
Kohli, V1
Andersson, BS4
Harousseau, JL2
Milpied, N1
Briere, J1
Desablens, B2
Le Prise, PY1
Ifrah, N1
Gandhour, C1
Casassus, P1
Davis, CL1
Rohatiner, AZ1
Amess, J1
Lim, J1
Estienne, MH1
Fenaux, P1
Preudhomme, C1
Lai, JL1
Zandecki, M1
Lepelley, P1
Cosson, A1
Dekker, AW1
Nieuwenhuis, HK1
De Pauw, B1
Marcus, RE1
Catovsky, D1
Newland, AC1
Chessells, JM1
Stevens, RF1
Hann, IM1
Goldman, JM1
Hoffbrand, AV1
Galton, DA1
Gray, R2
Hayhoe, FG1
Rice, A1
Vezon, G1
Abels, J1
Bury, J2
Hayat, M1
Amadori, S1
Pulsoni, A2
Sandrelli, A2
Linkesch, W1
Michlmayr, G1
Gerhartz, H1
Illinger, H1
König, H1
Düllmann, J1
Keilhauer, R1
Moldrzyk, D1
Geller, RB1
Humphrey, RL1
Braine, HG1
Tucker, RW1
Fox, MG1
Zahurak, M1
Morrell, L1
Hall, KL1
Mukaiyama, T1
Horikoshi, N1
Inoue, K1
Fukutani, H1
Tabata, M1
Hirano, A1
Mizunuma, N1
Itami, S1
Kalwinsky, DK1
Grier, HE1
Mason, C1
Murphy, SB1
Dahl, GV1
Hoffman, MS1
Turnquist, D1
Bakic, M2
Chan, D1
Marton, LJ1
Gaynor, J1
Miller, W1
Kempin, SJ1
Andreeff, M1
Reich, L1
Nahmias, N1
Sahyoun, N1
Wolf, M1
Besterman, J1
Hsieh, T1
Sander, M1
LeVine, H1
Chang, KJ1
Cuatrecasas, P1
Silberman, LE1
Newman, RA1
Silberman, L1
Jager, U1
Burghouts, J1
Walters, R1
Smith, T1
Blanc, CM1
Peters, WG4
Colly, LP2
Carter, C1
Winfield, DA1
Knüppel, W1
Wilmanns, W1
Bolwell, BJ1
Lepage, E1
Guy, H1
Bordessoule, D1
Guilhot, F1
Boiron, M1
Covelli, A1
Simone, F1
Tschopp, L1
von Fliedner, VE1
Sauter, C1
Maurice, P1
Gratwohl, A1
Fopp, M1
Cavalli, F1
Dalton, WT1
Cork, A1
Trujillo, JM1
Brox, LW1
Belch, A1
Ng, A1
Pollock, E1
Dhaliwal, HS1
Barnett, MJ1
Bragman, K1
Hagenbeek, A1
Martens, AC1
Child, JA1
Norfolk, DR1
Franks, CR1
Nys, G1
Ossenkoppele, GJ1
van der Weide, M1
Wijngaarden, MJ1
Reijneke, RM1
Wijermans, PW1
Langenhuijsen, MM1
Delanian, S1
Decker, RW1
Ho, WG1
Berthold, F1
Lampert, F1
Roubenoff, R1
Stevens, MB1
Tham, RT1
de Bruïne, FT1
Gottlieb, AJ1
Goldberg, J1
Brennan, J1
Grunwald, H1
Rai, K1
Browman, G1
Miller, KB1
Feldman, E1
Weinstein, P1
Rieber, E1
Sullivan, P1
Jurlina, JL1
Varcoe, AR1
Paxton, JW1
van Hennik, MB1
Fibbe, WE1
Kootte, AM1
van Berkel, M1
Lie, R1
Rodenburg, CJ1
Veltkamp, JJ1
Kucuk, O1
Apostol, JV1
David, B1
Broustet, A1
Zittoun, J1
Marquet, J1

Clinical Trials (10)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Reduced Intensity Conditioning With Fludarabine and Busulfan Versus Fludarabine and Melphalan Before Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Randomised, Single-Center, Phase III Study[NCT05674539]Phase 3200 participants (Anticipated)Interventional2022-12-28Recruiting
AML2003 - Randomized Comparison Between Standard-Therapy and Intensified Therapy for Adult Acute Myeloid Leukemia Patients <= 60 Years. A Prospective, Randomized, Multi-center Therapy-Optimizing-Study.[NCT00180102]Phase 4600 participants (Anticipated)Interventional2003-12-31Completed
Eradicating Measurable Residual Disease in Patients With Acute Myeloid Leukemia (AML) Prior to StEm Cell Transplantation (ERASE): A MyeloMATCH Treatment Trial[NCT05628623]Phase 2184 participants (Anticipated)Interventional2023-10-23Not yet recruiting
Treatment of Newly Diagnosed Childhood Acute Myeloid Leukemia (AML) Using Intensive MRC-Based Therapy and Gemtuzumab Ozogamicin (GMTZ): A COG Pilot Study[NCT00070174]Phase 2350 participants (Actual)Interventional2003-12-31Completed
Early Tapering of Immunosuppressive Agents After Allogeneic Hematopoietic Stem Cell Transplantation Can Improve the Survival of Patients With Advanced Acute Myeloid Leukemia.[NCT03150134]Phase 4100 participants (Anticipated)Interventional2010-01-01Recruiting
DaunoXome (Liposomal Daunorubicin) Plus Ara-C Versus Daunorubicin Plus Ara-C in Elderly AML Patients.A Randomized Phase III Study.[NCT00589082]Phase 30 participants Interventional2001-10-31Completed
Feasibility Study of the Use of Intermediate Doses of Cytarabine Associated With Autologous Hematopoietic Stem Cells as Consolidation Treatment of Young Adults With Low- or Intermediate-risk de Novo Acute Myeloid Leukemia[NCT03023384]547 participants (Anticipated)Observational [Patient Registry]2016-12-31Recruiting
Prophylactic Infusion of Donor Lymphocytes in Cord Blood Transplantation[NCT02328885]Phase 1/Phase 217 participants (Actual)Interventional2014-07-31Completed
Multicenter Protocol in Treating Patients With Childhood Acute Myeloid Leukemia. Randomized Study of Maintenance Treatment With Interleukin-2[NCT00149162]Phase 3580 participants (Anticipated)Interventional2005-03-31Recruiting
A Multi-Center Phase 2 Study of Daratumumab With Pomalidomide and Dexamethasone in Combination With All-Transretinoic Acid in Patients With Multiple Myeloma Previously Exposed to Daratumumab-Based Regimens[NCT04700176]Phase 243 participants (Anticipated)Interventional2022-05-02Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

6 reviews available for amsacrine and Acute Myelogenous Leukemia

ArticleYear
Toxic megacolon complicating chemotherapy for acute myeloid leukaemia.
    Postgraduate medical journal, 1994, Volume: 70, Issue:830

    Topics: Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Etoposid

1994
New drugs in acute myelogenous leukemia: a review.
    Journal of clinical pharmacology, 1992, Volume: 32, Issue:4

    Topics: Amsacrine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as

1992
Evolution of treatment for acute myelogenous leukemia and myelodysplastic syndrome at M.D. Anderson Cancer Center 1985-1991.
    Leukemia, 1992, Volume: 6 Suppl 2

    Topics: Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Administra

1992
Mitoxantrone and amsacrine: two important agents for the treatment of acute myelogenous leukemia (AML) and acute lymphoblastic leukemia (ALL).
    Bone marrow transplantation, 1989, Volume: 4 Suppl 1

    Topics: Amsacrine; Daunorubicin; Drug Evaluation; Humans; Leukemia, Myeloid, Acute; Mitoxantrone; Precursor

1989
High dose cytarabine: a review.
    Leukemia, 1988, Volume: 2, Issue:5

    Topics: Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cytarabine; Daunorubicin; H

1988
Amsacrine: a review.
    Leukemia research, 1986, Volume: 10, Issue:11

    Topics: Amsacrine; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemical

1986

Trials

59 trials available for amsacrine and Acute Myelogenous Leukemia

ArticleYear
Augmented Reduced-Intensity Regimen Does Not Improve Postallogeneic Transplant Outcomes in Acute Myeloid Leukemia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2021, 03-01, Volume: 39, Issue:7

    Topics: Adult; Aged; Amsacrine; Busulfan; Cytarabine; Female; Graft vs Host Disease; Humans; Immunosuppressi

2021
High-dose cytarabine consolidation with or without additional amsacrine and mitoxantrone in acute myeloid leukemia: results of the prospective randomized AML2003 trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Jun-10, Volume: 31, Issue:17

    Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Ther

2013
Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML.
    Cancer, 2015, Jan-15, Volume: 121, Issue:2

    Topics: Adult; Aged; Aminoglycosides; Amsacrine; Antibodies, Monoclonal, Humanized; Antineoplastic Combined

2015
Early allo-SCT for AML with a complex aberrant karyotype--results from a prospective pilot study.
    Bone marrow transplantation, 2012, Volume: 47, Issue:1

    Topics: Abnormal Karyotype; Acute Disease; Adolescent; Adult; Amsacrine; Antilymphocyte Serum; Antineoplasti

2012
Upfront allogeneic blood stem cell transplantation for patients with high-risk myelodysplastic syndrome or secondary acute myeloid leukemia using a FLAMSA-based high-dose sequential conditioning regimen.
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2012, Volume: 18, Issue:3

    Topics: Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide;

2012
Risk-adapted induction and consolidation therapy in adults with de novo AML aged
    Annals of hematology, 2004, Volume: 83, Issue:6

    Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Ther

2004
Phase II trial of amsacrine plus intermediate-dose Ara-C (IDAC) with or without etoposide as salvage therapy for refractory or relapsed acute leukemia.
    Japanese journal of clinical oncology, 2005, Volume: 35, Issue:10

    Topics: Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Diar

2005
Amsacrine containing induction therapy in elderly AML patients: comparison to standard induction regimens in a matched-pair analysis.
    Leukemia research, 2008, Volume: 32, Issue:3

    Topics: Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Drug Admi

2008
[Current status of the treatment of recurrent acute myeloblastic leukaemia in adults (author's transl)].
    Sangre, 1981, Volume: 26, Issue:5B

    Topics: Aminoacridines; Amsacrine; Antineoplastic Agents; Azacitidine; Clinical Trials as Topic; Daunorubici

1981
Premature chromosome condensation studies in human leukemia: 5. Prediction of early relapse.
    Blood, 1984, Volume: 64, Issue:5

    Topics: Aminoacridines; Amsacrine; Animals; Cell Fusion; Chromosomes; Clinical Trials as Topic; Cricetinae;

1984
Primary therapy of acute promyelocytic leukemia: results of amsacrine- and daunorubicin-based therapy.
    Blood, 1984, Volume: 63, Issue:1

    Topics: Adult; Aged; Aminoacridines; Amsacrine; Antibiotics, Antineoplastic; Antineoplastic Combined Chemoth

1984
[Clinical activity of m-Amsa and the combination of m-Amsa with cytosine arabinoside].
    La Nouvelle presse medicale, 1982, Oct-09, Volume: 11, Issue:39

    Topics: Adolescent; Adult; Aminoacridines; Amsacrine; Antineoplastic Agents; Child; Clinical Trials as Topic

1982
AMSA--a promising new agent in refractory acute leukemia.
    Cancer treatment reports, 1982, Volume: 66, Issue:7

    Topics: Acute Disease; Adolescent; Adult; Aged; Aminoacridines; Amsacrine; Antineoplastic Agents; Child; Cli

1982
Trial of AMSA in acute leukemia.
    Cancer treatment reports, 1982, Volume: 66, Issue:7

    Topics: Adolescent; Adult; Aminoacridines; Amsacrine; Antineoplastic Agents; Child; Clinical Trials as Topic

1982
Long-term follow-up of a randomized post-induction therapy trial in acute myelogenous leukemia (a Southeastern Cancer Study Group trial).
    Leukemia, 1995, Volume: 9, Issue:9

    Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cytarabin

1995
Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (
    The New England journal of medicine, 1995, Jan-26, Volume: 332, Issue:4

    Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplant

1995
Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (
    The New England journal of medicine, 1995, Jan-26, Volume: 332, Issue:4

    Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplant

1995
Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (
    The New England journal of medicine, 1995, Jan-26, Volume: 332, Issue:4

    Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplant

1995
Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (
    The New England journal of medicine, 1995, Jan-26, Volume: 332, Issue:4

    Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplant

1995
Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (
    The New England journal of medicine, 1995, Jan-26, Volume: 332, Issue:4

    Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplant

1995
Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (
    The New England journal of medicine, 1995, Jan-26, Volume: 332, Issue:4

    Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplant

1995
Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (
    The New England journal of medicine, 1995, Jan-26, Volume: 332, Issue:4

    Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplant

1995
Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (
    The New England journal of medicine, 1995, Jan-26, Volume: 332, Issue:4

    Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplant

1995
Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (
    The New England journal of medicine, 1995, Jan-26, Volume: 332, Issue:4

    Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplant

1995
Long-term results following treatment of newly-diagnosed acute myelogenous leukemia with continuous-infusion high-dose cytosine arabinoside.
    Leukemia, 1994, Volume: 8, Issue:8

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amsacrine; Antineoplastic Combined Chemotherapy Protocol

1994
Efficacy of etoposide and mitoxantrone in patients with acute myelogenous leukemia refractory to standard induction therapy and intermediate-dose cytarabine with amsidine. Dutch Hematology-Oncology Working Group for Adults (HOVON).
    Leukemia, 1994, Volume: 8, Issue:1

    Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Respo

1994
[Phase II clinical trial of domestic amsacrine in patients with acute leukemias. Cooperative Group for Treating Acute Leukemias with Domestic m-AMSA].
    Zhonghua nei ke za zhi, 1993, Volume: 32, Issue:2

    Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relation

1993
Phase-II study of treatment of refractory acute leukemia with intermediate-dose cytosine arabinoside and amsacrine.
    Annals of hematology, 1993, Volume: 66, Issue:3

    Topics: Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug

1993
[Comparison between intensive consolidation by bone marrow autograft or by chemotherapy of acute myeloblastic leukemias in 1st complete remission: AML8A protocol of the Leukemia Cooperative Group of the European Organization for Research and Treatment of
    Nouvelle revue francaise d'hematologie, 1993, Volume: 35, Issue:1

    Topics: Actuarial Analysis; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplan

1993
Therapy of refractory or recurrent childhood acute myeloid leukemia using amsacrine and etoposide with or without azacitidine: a Pediatric Oncology Group randomized phase II study.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1996, Volume: 14, Issue:5

    Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Child; Ch

1996
BAVC regimen and autograft for acute myelogenous leukemia in second complete remission.
    Bone marrow transplantation, 1996, Volume: 18, Issue:4

    Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplant

1996
A randomized phase II study on the effects of 5-Aza-2'-deoxycytidine combined with either amsacrine or idarubicin in patients with relapsed acute leukemia: an EORTC Leukemia Cooperative Group phase II study (06893).
    Leukemia, 1997, Volume: 11 Suppl 1

    Topics: Adolescent; Adult; Aged; Amsacrine; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemoth

1997
Comparison of efficacies of ondansetron and dixyrazine for prophylaxis of emesis during induction treatment in acute myelogenous leukemia. A pilot study.
    Acta oncologica (Stockholm, Sweden), 1997, Volume: 36, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Amsacrine; Antiemetics; Antineoplastic Combined Chemotherapy Protoco

1997
Comparison between four and eight cycles of intensive chemotherapy in adult acute myeloid leukemia: a randomized trial of the Finnish Leukemia Group.
    Leukemia, 1998, Volume: 12, Issue:7

    Topics: Aclarubicin; Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cyt

1998
Randomised unicenter trial for comparison of three regimens in de novo adult acute nonlymphoblastic leukaemia.
    Medical oncology (Northwood, London, England), 1998, Volume: 15, Issue:3

    Topics: Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daun

1998
High single dose of mitoxantrone and cytarabine in acute non-lymphocytic leukemia: a pharmacokinetic and clinical study.
    Therapeutic drug monitoring, 1998, Volume: 20, Issue:6

    Topics: Adult; Aged; Amsacrine; Chromatography, High Pressure Liquid; Cytarabine; Drug Administration Schedu

1998
Impact of addition of maintenance therapy to intensive induction and consolidation chemotherapy for childhood acute myeloblastic leukemia: results of a prospective randomized trial, LAME 89/91. Leucámie Aiqüe Myéloïde Enfant.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2002, Jun-15, Volume: 20, Issue:12

    Topics: Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow Transplantation

2002
AMSA combination chemotherapy in patients with acute myelogenous leukemia unsuitable for standard antileukemic treatment.
    Leukemia & lymphoma, 1992, Volume: 8, Issue:4-5

    Topics: Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Heart Di

1992
Current strategies for treatment of acute myeloid leukemia at St Jude Children's Research Hospital.
    Leukemia, 1992, Volume: 6 Suppl 2

    Topics: 2-Chloroadenosine; Acute Disease; Adolescent; Adult; Amsacrine; Antineoplastic Agents; Antineoplasti

1992
[Effects of alternating as well as long-term intensive polychemotherapy in the remission-maintaining treatment of patients with acute myelocytic leukemia].
    Polskie Archiwum Medycyny Wewnetrznej, 1992, Volume: 87, Issue:2

    Topics: Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Doxo

1992
DNA as a carrier for anthracyclines in the treatment of acute myelocytic leukemia (AML).
    Leukemia, 1992, Volume: 6 Suppl 2

    Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubic

1992
Remission induction and postremission therapy in acute myelogenous leukemia: British MRC Study.
    Haematology and blood transfusion, 1990, Volume: 33

    Topics: Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bon

1990
A randomized comparison of intensive maintenance treatment for adult acute myelogenous leukemia using either cyclic alternating drugs or repeated courses of the induction-type chemotherapy: AML-6 trial of the EORTC Leukemia Cooperative Group.
    Haematology and blood transfusion, 1990, Volume: 33

    Topics: Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bel

1990
Intermediate-dose Ara-C/m-AMSA for remission induction and high-dose Ara-C/m-AMSA for intensive consolidation in relapsed and refractory adult acute myelogeneous leukemia.
    Haematology and blood transfusion, 1990, Volume: 33

    Topics: Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bon

1990
Successful reinduction therapy with amsacrine and cyclocytidine in acute nonlymphoblastic leukemia in children. A report from the Childrens Cancer Study Group.
    Cancer, 1991, May-01, Volume: 67, Issue:9

    Topics: Adolescent; Amsacrine; Ancitabine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Chil

1991
Toxicity trials of amsacrine (AMSA) and etoposide +/- azacitidine (AZ) in childhood acute non-lymphocytic leukemia (ANLL): a pilot study.
    Investigational new drugs, 1991, Volume: 9, Issue:2

    Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Child; Ch

1991
[Autotransplantation in acute nonlymphoid leukemia].
    Haematologica, 1991, Volume: 76 Suppl 3

    Topics: Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Bone Marrow Transpla

1991
BAVC regimen in CR AML patients.
    Bone marrow transplantation, 1991, Volume: 7 Suppl 2

    Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplant

1991
Aclarubicin plus cytosine arabinoside versus daunorubicin plus cytosine arabinoside in previously untreated patients with acute myeloid leukemia: a Danish national phase III trial. The Danish Society of Hematology Study Group on AML, Denmark.
    Leukemia, 1991, Volume: 5, Issue:6

    Topics: Aclarubicin; Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Chi

1991
Comparison of postremission therapies in adult acute myeloid leukemia: preliminary analysis of an ECOG study. Eastern Cooperative Oncology Group.
    Haematology and blood transfusion, 1990, Volume: 33

    Topics: Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Tran

1990
High-dose cytosine arabinoside and amsacrine or mitoxantrone in relapsed and refractory acute myeloid leukaemia: a prospective randomized study.
    European journal of haematology, 1990, Volume: 45, Issue:3

    Topics: Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans;

1990
Therapy of acute myelogenous leukemia in patients over the age of 50: a randomized Southeastern Cancer Study Group trial.
    Leukemia research, 1990, Volume: 14, Issue:10

    Topics: Aged; Aged, 80 and over; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daun

1990
Intensive induction and consolidation chemotherapy for adults and children with acute myeloid leukaemia (AML) joint AML trial 1982-1985.
    Haematology and blood transfusion, 1987, Volume: 30

    Topics: Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Child; Clinical Trial

1987
The ninth British Medical Research Council trial for the treatment of acute myeloid leukaemia.
    Haematology and blood transfusion, 1987, Volume: 30

    Topics: Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Clinical Trials as Topic; Cy

1987
[AML-6 study of the value of cyclic alternating chemotherapy during remission in acute myelocytic leukemia].
    Onkologie, 1985, Volume: 8, Issue:2

    Topics: Adult; Aminoacridines; Amsacrine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoc

1985
Alternating v repeated postremission treatment in adult acute myelogenous leukemia: a randomized phase III study (AML6) of the EORTC Leukemia Cooperative Group.
    Blood, 1989, Volume: 73, Issue:4

    Topics: Adolescent; Adult; Aged; Amsacrine; Child; Clinical Trials as Topic; Cytarabine; Daunorubicin; Human

1989
Amsacrine, cytarabine and thioguanine (AAT) versus daunorubicin, cytarabine, thioguanine (DAT) in adults with untreated acute non-lymphoblastic leukemia (ANLL). Austrian-German results.
    Onkologie, 1989, Volume: 12, Issue:1

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amsacrine; Antineoplastic Combined Chemotherapy Protocol

1989
A two-step timed sequential treatment for acute myelocytic leukemia.
    Blood, 1989, Volume: 74, Issue:5

    Topics: Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials

1989
Comparative trial of cytarabine and thioguanine in combination with amsacrine or daunorubicin in patients with untreated acute nonlymphocytic leukemia: results of the L-16M protocol.
    Leukemia, 1989, Volume: 3, Issue:2

    Topics: Age Factors; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Dr

1989
Intensive maintenance treatment in acute myelogenous leukemia (AML): single institution experience of a multicenter randomized trial.
    Onkologie, 1988, Volume: 11, Issue:1

    Topics: Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials

1988
Remission induction and maintenance modalities in acute myeloid leukemia: a multicenter randomized study.
    Haematology and blood transfusion, 1987, Volume: 30

    Topics: Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Cyclophosphamid

1987
Comparison of 1 + 5 DAT and 3 + 10 DAT followed by COAP or MAZE consolidation therapy in the treatment of acute myeloid leukemia: MRC ninth AML trial.
    Seminars in oncology, 1987, Volume: 14, Issue:2 Suppl 1

    Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Amsacrine; Antineoplastic Combined Chemothe

1987
Results of induction and consolidation treatment with intermediate and high-dose ara-C and m-AMSA containing regimens in patients with primarily failed or relapsed acute leukemia and non-Hodgkin's lymphoma.
    Scandinavian journal of haematology. Supplementum, 1986, Volume: 44

    Topics: Adolescent; Adult; Aminoacridines; Amsacrine; Antineoplastic Agents; Antineoplastic Combined Chemoth

1986
Randomized trial of high-dose cytarabine versus amsacrine in acute myelogenous leukemia in relapse: a Leukemia Intergroup Study.
    Cancer treatment reports, 1986, Volume: 70, Issue:4

    Topics: Adolescent; Adult; Aged; Aminoacridines; Amsacrine; Antibiotics, Antineoplastic; Bone Marrow; Clinic

1986
Amsacrine: a review.
    Leukemia research, 1986, Volume: 10, Issue:11

    Topics: Amsacrine; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemical

1986
A new regimen of amsacrine with high-dose cytarabine is safe and effective therapy for acute leukemia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1987, Volume: 5, Issue:3

    Topics: Acute Disease; Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; B

1987
[AML-6 and AML-7 studies on the treatment of acute myelocytic leukemia. Cyclic alternating chemotherapy during remission, and induction of remission and survival of elderly patients].
    Onkologie, 1985, Volume: 8, Issue:3

    Topics: Adult; Age Factors; Aged; Aminoacridines; Amsacrine; Antineoplastic Agents; Antineoplastic Combined

1985

Other Studies

95 other studies available for amsacrine and Acute Myelogenous Leukemia

ArticleYear
Impact on Outcome of Minimal Residual Disease after Hematopoietic Stem Cell Transplantation with Fludarabine, Amsacrine, and Cytosine Arabinoside-Busulfan Conditioning: A Retrospective Monocentric Study.
    Transplantation and cellular therapy, 2023, Volume: 29, Issue:1

    Topics: Amsacrine; Busulfan; Cytarabine; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid,

2023
Amsacrine-based induction therapy in AML patients with cardiac comorbidities: a retrospective single-center analysis.
    Annals of hematology, 2023, Volume: 102, Issue:4

    Topics: Amsacrine; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Heart Disease

2023
Combination of fludarabine, amsacrine, and cytarabine followed by reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation in patients with high-risk acute myeloid leukemia.
    Annals of hematology, 2013, Volume: 92, Issue:10

    Topics: Adult; Amsacrine; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; C

2013
Transplant-acquired food allergy (TAFA) following cord blood stem cell transplantation in two adult patients with haematological malignancies.
    British journal of haematology, 2014, Volume: 167, Issue:3

    Topics: Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cord Bl

2014
Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantation.
    Journal of cancer research and clinical oncology, 2016, Volume: 142, Issue:1

    Topics: Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; C

2016
Sequential Intensified Conditioning Regimen Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Intermediate- or High-Risk Acute Myeloid Leukemia in Complete Remission: A Study from the Acute Leukemia Working Party of the European Gr
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2017, Volume: 23, Issue:2

    Topics: Adolescent; Adult; Aged; Allografts; Amsacrine; Bone Marrow Transplantation; Busulfan; Cyclophospham

2017
Poor-risk cytogenetics may be associated with inferior outcome after fludarabine, cytarabine, and amsacrine reduced intensity conditioning in patients with high-risk acute myeloid leukemia.
    Leukemia & lymphoma, 2011, Volume: 52, Issue:10

    Topics: Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Cytogenetics; Female;

2011
AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: a report from the Children's Oncology Group.
    Cancer, 2012, Feb-01, Volume: 118, Issue:3

    Topics: Adolescent; Adult; Aminoglycosides; Amsacrine; Antibodies, Monoclonal, Humanized; Antineoplastic Com

2012
Fludarabine, cytarabine, granulocyte-colony stimulating factor and amsacrine: an effective salvage therapy option for acute myeloid leukemia at first relapse.
    Leukemia & lymphoma, 2013, Volume: 54, Issue:2

    Topics: Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Fema

2013
Factors influencing outcome and incidence of long-term complications in children who underwent autologous stem cell transplantation for acute myeloid leukemia in first complete remission.
    Blood, 2003, Feb-15, Volume: 101, Issue:4

    Topics: Adolescent; Amsacrine; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Bone Ma

2003
Comparison of BAVC to BuCy regimens in autologous stem cell transplantation for adult patients with acute myeloid leukemia.
    Haematologica, 2004, Volume: 89, Issue:1

    Topics: Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Carmus

2004
Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Aug-20, Volume: 23, Issue:24

    Topics: Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Chi-Square Distr

2005
Usefulness of PKH fluorescent labelling to study leukemic cell proliferation with various cytostatic drugs or acetyl tetrapeptide--AcSDKP.
    BMC cancer, 2005, Sep-20, Volume: 5

    Topics: Amsacrine; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Br

2005
The high incidence of varicella herpes zoster with the use of bortezomib in 10 patients.
    American journal of hematology, 2007, Volume: 82, Issue:5

    Topics: Adult; Aged; Amsacrine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boron

2007
Addition of PTK787/ZK 222584 can lower the dosage of amsacrine to achieve equal amounts of acute myeloid leukemia cell death.
    Anti-cancer drugs, 2008, Volume: 19, Issue:1

    Topics: Amsacrine; Antineoplastic Agents; Cell Death; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Syne

2008
[Treatment of acute myeloid leukemia].
    Folia haematologica (Leipzig, Germany : 1928), 1984, Volume: 111, Issue:2

    Topics: Adult; Aminoacridines; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine;

1984
[Phase II study of AMSA in adults with acute therapy-refractory leukemias].
    Onkologie, 1983, Volume: 6, Issue:4

    Topics: Adolescent; Adult; Aged; Aminoacridines; Amsacrine; Antineoplastic Agents; Drug Evaluation; Humans;

1983
[Combined therapy with AMSA and etoposide (VP 16-213) in refractory acute myeloid leukemia. A phase I study].
    Onkologie, 1984, Volume: 7, Issue:4

    Topics: Aminoacridines; Amsacrine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dr

1984
Case of refractory acute myeloblastic leukemia who achieved complete remission by a new anti-leukemic agent, 4'-(9-acridinylamino) methanesulfon-m-anisidide (AMSA).
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 1983, Volume: 24, Issue:5

    Topics: Adult; Aminoacridines; Amsacrine; Antineoplastic Agents; Female; Humans; Leukemia, Myeloid, Acute

1983
Amsacrine in refractory adult acute leukemia: a pilot study of the Southeastern Cancer Study Group.
    Cancer treatment reports, 1983, Volume: 67, Issue:11

    Topics: Adolescent; Adult; Aged; Aminoacridines; Amsacrine; Bone Marrow; Drug Evaluation; Female; Humans; Hy

1983
Phase II study of amsacrine gluconate in refractory leukemia.
    Cancer treatment reports, 1983, Volume: 67, Issue:12

    Topics: Adult; Aged; Aminoacridines; Amsacrine; Drug Evaluation; Female; Gluconates; Humans; Lactates; Leuke

1983
Prediction of complete remission in patients with refractory acute leukemia treated with AMSA.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1984, Volume: 2, Issue:2

    Topics: Acute Disease; Adult; Aminoacridines; Amsacrine; Female; Humans; Leukemia; Leukemia, Lymphoid; Leuke

1984
AMSA: a phase II trial in resistant and recurrent acute myelogenous leukemia.
    Medical and pediatric oncology, 1984, Volume: 12, Issue:3

    Topics: Aminoacridines; Amsacrine; Drug Evaluation; Drug Resistance; Humans; Leukemia, Myeloid, Acute; Recur

1984
m-AMSA: phase II trial in advanced lymphoma and leukemia.
    American journal of clinical oncology, 1984, Volume: 7, Issue:4

    Topics: Acute Disease; Adolescent; Adult; Aged; Aminoacridines; Amsacrine; Antineoplastic Agents; Bone Marro

1984
A non-clonogenic assay for the determination of the sensitivity of leukemic cells to chemotherapeutic agents.
    European journal of cancer & clinical oncology, 1983, Volume: 19, Issue:11

    Topics: Aclarubicin; Aminoacridines; Amsacrine; Antineoplastic Agents; Bone Marrow; Cell Division; Cell Surv

1983
4'-(9-Acridinylamino) methanesulfon-m-anisidide (AMSA): a new drug effective in the treatment of adult acute leukemia.
    Annals of internal medicine, 1980, Volume: 93, Issue:1

    Topics: Adolescent; Adult; Aged; Aminoacridines; Amsacrine; Bone Marrow; Dose-Response Relationship, Drug; D

1980
Amsacrine (AMSA).
    Cancer treatment reviews, 1980, Volume: 7, Issue:2

    Topics: Aminoacridines; Amsacrine; Animals; Antineoplastic Agents; Breast Neoplasms; Dogs; Dose-Response Rel

1980
Self-renewal capacity of leukemic blast progenitor cells.
    Cancer research, 1981, Volume: 41, Issue:11 Pt 2

    Topics: Aminoacridines; Amsacrine; Cell Division; Clone Cells; Cytarabine; Dose-Response Relationship, Drug;

1981
A phase I and II study of m-AMSA in acute leukaemia.
    Cancer chemotherapy and pharmacology, 1981, Volume: 6, Issue:2

    Topics: Adolescent; Adult; Aged; Aminoacridines; Amsacrine; Antineoplastic Agents; Child; Child, Preschool;

1981
Evaluation of AMSA in previously treated patients with acute leukemia: results of therapy in 109 adults.
    Blood, 1982, Volume: 60, Issue:2

    Topics: Acute Disease; Aminoacridines; Amsacrine; Antineoplastic Agents; Dose-Response Relationship, Drug; H

1982
Phase I and II study of AMSA in childhood tumours.
    Cancer chemotherapy and pharmacology, 1982, Volume: 9, Issue:1

    Topics: Adolescent; Aminoacridines; Amsacrine; Antineoplastic Agents; Child; Child, Preschool; Drug Administ

1982
Topoisomerase II levels and drug sensitivity in adult acute myelogenous leukemia.
    Blood, 1994, Jan-15, Volume: 83, Issue:2

    Topics: Amsacrine; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carrier Proteins; Daunorubicin;

1994
Interactions between cladribine (2-chlorodeoxyadenosine) and standard antileukemic drugs in primary cultures of human tumor cells from patients with acute myelocytic leukemia.
    Leukemia, 1994, Volume: 8, Issue:10

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amsacrine; Antineoplastic Agents; Cladribine; Cytarabine

1994
Treatment of relapsed acute myeloid leukemia using GM-CSF before intensive chemotherapy.
    Leukemia & lymphoma, 1993, Volume: 12, Issue:1-2

    Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Bone Mar

1993
Treatment of relapsing and refractory adult acute myeloid leukemia according to in vitro clonogenic leukemic cell drug sensitivity.
    Leukemia & lymphoma, 1993, Volume: 10, Issue:1-2

    Topics: Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Et

1993
Intensive induction and consolidation chemotherapy in a young woman with acute myeloid leukemia and severe chronic renal failure.
    Annals of hematology, 1996, Volume: 72, Issue:5

    Topics: Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Contraindications; Cytarabine; Dau

1996
Topoisomerase II inhibitors induce DNA double-strand breaks at a specific site within the AML1 locus.
    Leukemia, 1997, Volume: 11, Issue:4

    Topics: Amsacrine; Antineoplastic Agents; Base Sequence; Cell Line; Dactinomycin; DNA Damage; DNA, Neoplasm;

1997
In vitro cytotoxic drug activity and in vivo pharmacokinetics in childhood acute myeloid leukemia.
    Advances in experimental medicine and biology, 1999, Volume: 457

    Topics: Amsacrine; Antineoplastic Agents; Blast Crisis; Bone Marrow; Cell Survival; Child; Cytarabine; Doxor

1999
Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome.
    Blood, 2002, Jan-01, Volume: 99, Issue:1

    Topics: Amsacrine; Anthracyclines; Antineoplastic Agents; Busulfan; Cell Survival; Child; Child, Preschool;

2002
Multidrug resistance (MDR) gene expression in acute non lymphoblastic leukemia: sequential analysis.
    Leukemia & lymphoma, 1992, Volume: 8, Issue:4-5

    Topics: Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transpo

1992
Survival in 91 adults with acute myelogenous leukaemia treated with 1-6 intensive courses of chemotherapy.
    Journal of internal medicine, 1992, Volume: 232, Issue:5

    Topics: Actuarial Analysis; Adolescent; Adult; Age Factors; Amsacrine; Antineoplastic Combined Chemotherapy

1992
Double intensification with amsacrine/high dose ara-C and high dose chemotherapy with autologous bone marrow transplantation produces durable remissions in acute myelogenous leukemia.
    Bone marrow transplantation, 1990, Volume: 5, Issue:2

    Topics: Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Transplanta

1990
[Intensification chemotherapy followed by allogenieic and autologous bone marrow transplantation in acute non-lymphoblastic leukemia in children].
    Sangre, 1991, Volume: 36, Issue:1

    Topics: Adolescent; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation;

1991
The amsacrine story: will it change the FDA policy?
    Annals of oncology : official journal of the European Society for Medical Oncology, 1991, Volume: 2, Issue:4

    Topics: Amsacrine; Humans; Legislation, Drug; Leukemia, Myeloid, Acute; United States; United States Food an

1991
Amsacrine is safe and effective therapy for patients with myocardial dysfunction and acute leukemia.
    Cancer, 1991, Sep-15, Volume: 68, Issue:6

    Topics: Amsacrine; Cardiac Output, Low; Cytarabine; Drug Therapy, Combination; Humans; Leukemia; Leukemia, M

1991
[Extravasation of cytostatics. Example of a severe complication from the use of long-term central venous catheters].
    Ugeskrift for laeger, 1991, Oct-07, Volume: 153, Issue:41

    Topics: Amsacrine; Antineoplastic Agents; Catheterization, Central Venous; Equipment Failure; Extravasation

1991
Doxorubicin and m-AMSA induced DNA damage in blast cells from AML patients.
    Leukemia research, 1991, Volume: 15, Issue:1

    Topics: Adult; Aged; Amsacrine; DNA Damage; DNA, Single-Stranded; Doxorubicin; Female; Humans; Leukemia, Mye

1991
Pharmacokinetics of continuous-infusion amsacrine and teniposide for the treatment of relapsed childhood acute nonlymphocytic leukemia.
    Cancer chemotherapy and pharmacology, 1991, Volume: 27, Issue:5

    Topics: Adolescent; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Huma

1991
Resistance to 4-(9-acridinylamino) methanesulphon-m-anisidide (m-AMSA) in human myeloid leukaemia.
    British journal of cancer, 1990, Volume: 61, Issue:1

    Topics: Amsacrine; Cell Line; Cell Survival; DNA Damage; DNA, Neoplasm; Drug Resistance; Humans; Leukemia, M

1990
Cellular ara-CTP pharmacokinetics, response, and karyotype in newly diagnosed acute myelogenous leukemia.
    Leukemia, 1990, Volume: 4, Issue:2

    Topics: Amsacrine; Arabinofuranosylcytosine Triphosphate; Arabinonucleotides; Chromosome Deletion; Chromosom

1990
Double intensive consolidation chemotherapy (ICC) for acute myeloid leukemia.
    Haematology and blood transfusion, 1990, Volume: 33

    Topics: Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmu

1990
Treatment of recurrent acute myelogenous leukaemia at a single centre over a 10-year period.
    Haematology and blood transfusion, 1990, Volume: 33

    Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplant

1990
Prognostic value of dysmyelopoietic features in de novo acute myeloid leukaemia: a report on 132 patients.
    Clinical and laboratory haematology, 1990, Volume: 12, Issue:1

    Topics: Adolescent; Adult; Amsacrine; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Prot

1990
BAVC regimen and autologous bone marrow transplantation in patients with acute myelogenous leukemia in second remission.
    Blood, 1990, Jun-15, Volume: 75, Issue:12

    Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplant

1990
Intermediate-dose cytosine arabinoside and amsacrine. An effective regimen with low toxicity in refractory acute nonlymphocytic leukemia.
    Cancer, 1990, May-01, Volume: 65, Issue:9

    Topics: Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Female; Humans;

1990
Intensive antileukemic treatment of patients younger than 65 years with myelodysplastic syndromes and secondary acute myelogenous leukemia.
    Cancer, 1990, Sep-01, Volume: 66, Issue:5

    Topics: Adult; Age Factors; Amsacrine; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Pro

1990
The role of peripheral blood stem cells as rescue after myeloablative therapy.
    Bone marrow transplantation, 1989, Volume: 4 Suppl 1

    Topics: Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Combined Modality Ther

1989
Amsacrine, cytarabine and etoposide in the treatment of bad prognosis acute myeloid leukemia.
    Medical oncology and tumor pharmacotherapy, 1989, Volume: 6, Issue:3

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amsacrine; Antineoplastic Combined Chemotherapy Protocol

1989
A special role for amsacrine in the treatment of acute leukemia.
    Cancer investigation, 1989, Volume: 7, Issue:6

    Topics: Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Humans; Leukemia, Myeloid, Acute; Precurs

1989
Autologous bone marrow transplantation in patients with AML in second complete remission (CR).
    Bone marrow transplantation, 1989, Volume: 4 Suppl 1

    Topics: Adolescent; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation;

1989
[4'-(9-acridinylamino)-methanesulfon-m-aniside (AMSA) combination salvage therapy in refractory acute non-lymphocytic leukemia in adults].
    Gan to kagaku ryoho. Cancer & chemotherapy, 1989, Volume: 16, Issue:5

    Topics: Adolescent; Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daun

1989
Effective reinduction therapy for childhood acute nonlymphoid leukemia using simultaneous continuous infusions of teniposide and amsacrine.
    Cancer chemotherapy and pharmacology, 1989, Volume: 24, Issue:2

    Topics: Adolescent; Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Blast Crisis; Child; C

1989
Necrotizing fasciitis of the vulva during chemotherapy.
    Obstetrics and gynecology, 1989, Volume: 74, Issue:3 Pt 2

    Topics: Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Fasciitis; Female; Hum

1989
Effect of polyamine depletion by alpha-difluoromethylornithine or (2R,5R)-6-heptyne-2,5-diamine on drug-induced topoisomerase II-mediated DNA cleavage and cytotoxicity in human and murine leukemia cells.
    Cancer research, 1987, Dec-15, Volume: 47, Issue:24 Pt 1

    Topics: Alkynes; Amsacrine; Animals; Antineoplastic Agents; Cell Line; Cell Survival; Diamines; DNA; DNA Dam

1987
Protein kinase C phosphorylates topoisomerase II: topoisomerase activation and its possible role in phorbol ester-induced differentiation of HL-60 cells.
    Proceedings of the National Academy of Sciences of the United States of America, 1986, Volume: 83, Issue:6

    Topics: Aminoacridines; Amsacrine; Animals; Cell Differentiation; Cell Line; DNA Topoisomerases, Type II; Dr

1986
In vitro toxicity and DNA cleaving capacity of benzisoquinolinedione (nafidimide; NSC 308847) in human leukemia.
    Cancer research, 1987, Feb-15, Volume: 47, Issue:4

    Topics: Adenine; Amsacrine; Cell Line; Clone Cells; DNA; DNA Topoisomerases, Type I; Doxorubicin; Electropho

1987
The interaction between nuclear topoisomerase II activity from human leukemia cells, exogenous DNA, and 4'-(9-acridinylamino)methanesulfon-m-anisidide (m-AMSA) or 4-(4,6-O-ethylidene-beta-D-glucopyranoside) (VP-16) indicates the sensitivity of the cells t
    Biochemical and biophysical research communications, 1987, Apr-29, Volume: 144, Issue:2

    Topics: Amsacrine; Animals; Cell Line; Cell Nucleus; Crithidia; DNA; DNA Topoisomerases, Type II; Humans; Ki

1987
Intermediate and high dose Ara-C and m-AMSA for remission induction and consolidation treatment of patients with acute myeloid leukemia: an EORTC Leukemia Cooperative Group phase II study.
    European journal of cancer & clinical oncology, 1988, Volume: 24, Issue:11

    Topics: Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation;

1988
Continuous-infusion amsacrine in patients with refractory acute myelogenous leukemia.
    Cancer treatment reports, 1987, Volume: 71, Issue:11

    Topics: Adult; Amsacrine; Diagnosis-Related Groups; Humans; Leukemia, Myeloid, Acute

1987
Comparison of results of salvage therapy in adult acute myelogenous leukemia.
    Acta haematologica, 1987, Volume: 78 Suppl 1

    Topics: Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Doxorubi

1987
[Combination of AMSA-high dose cytosine arabinoside in acute leukemia].
    Presse medicale (Paris, France : 1983), 1985, Jun-29, Volume: 14, Issue:26

    Topics: Adolescent; Adult; Aged; Aminoacridines; Amsacrine; Antineoplastic Combined Chemotherapy Protocols;

1985
Results of induction and consolidation treatment with intermediate and high-dose cytosine arabinoside and m-Amsa of patients with poor-risk acute myelogenous leukaemia.
    European journal of haematology, 1988, Volume: 40, Issue:3

    Topics: Adult; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Administration Sc

1988
Factor X deficiency during treatment of relapsed acute myeloid leukaemia with amsacrine.
    Clinical and laboratory haematology, 1988, Volume: 10, Issue:2

    Topics: Adult; Amsacrine; Blood Transfusion; Drug Therapy, Combination; Etoposide; Factor IX; Factor X; Fact

1988
Autologous bone marrow transplantation for patients with acute myelogenous leukemia in complete remission.
    Annals of the New York Academy of Sciences, 1987, Volume: 511

    Topics: Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Carmustine;

1987
Efficacy and clinical cross-resistance of a new combination therapy (AMSA/VP16) in previously treated patients with acute nonlymphocytic leukemia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1986, Volume: 4, Issue:3

    Topics: Adolescent; Adult; Aged; Aminoacridines; Amsacrine; Antineoplastic Combined Chemotherapy Protocols;

1986
Acute promyelocytic leukemia. M.D. Anderson Hospital experience.
    The American journal of medicine, 1986, Volume: 80, Issue:5

    Topics: Aminoacridines; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Cytara

1986
Loss of viability and induction of DNA damage in human leukemic myeloblasts and lymphocytes by m-AMSA.
    Cancer chemotherapy and pharmacology, 1986, Volume: 17, Issue:2

    Topics: Aminoacridines; Amsacrine; Cell Cycle; Cell Line; Cell Survival; DNA; DNA Repair; DNA, Neoplasm; Dos

1986
Treatment of acute leukaemia with m-AMSA in combination with cytosine arabinoside.
    Cancer chemotherapy and pharmacology, 1986, Volume: 18, Issue:1

    Topics: Aged; Amsacrine; Chemical and Drug Induced Liver Injury; Cytarabine; Female; Gastrointestinal Diseas

1986
Development and characterization of a human myelogenous leukemia cell line resistant to 4'-(9-acridinylamino)-3-methanesulfon-m-anisidide.
    Cancer research, 1987, Apr-01, Volume: 47, Issue:7

    Topics: Amsacrine; Cell Division; Cell Line; Doxorubicin; Drug Resistance; Karyotyping; Kinetics; Leukemia,

1987
AMSA: in vivo log cell kill for leukemic clonogenic cells versus toxicity for normal hemopoietic stem cells in a rat model for human acute myelocytic leukemia (BNML).
    European journal of cancer & clinical oncology, 1986, Volume: 22, Issue:10

    Topics: Amsacrine; Animals; Clone Cells; Colony-Forming Units Assay; Disease Models, Animal; Hematopoietic S

1986
m-AMSA and VP-16 combinations in the treatment of acute myeloid leukemia.
    British journal of haematology, 1987, Volume: 65, Issue:2

    Topics: Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Humans; Leukemia, Myeloid, Acu

1987
High-dose busulfan and amsacrine with autologous bone marrow rescue in patients with acute myeloid leukemia in first remission.
    Cancer treatment reports, 1987, Volume: 71, Issue:5

    Topics: Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Female; Humans; Leukemia, Myelo

1987
Prognostic value of in vitro uptake and retention of cytosine arabinoside in acute myelogenous leukemia.
    Seminars in oncology, 1987, Volume: 14, Issue:2 Suppl 1

    Topics: Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cytarabine; Daunorubicin; Hu

1987
Intensive treatment of acute leukemia in adults 70 years of age and older.
    Cancer, 1987, Jul-15, Volume: 60, Issue:2

    Topics: Aged; Aged, 80 and over; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daun

1987
Phase II study of amsacrine and high-dose cytarabine for resistant acute myelogenous leukemia.
    Cancer treatment reports, 1987, Volume: 71, Issue:9

    Topics: Adult; Aged; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Evaluation;

1987
Effective remission induction in children with recurrent acute myeloid leukemia by mAMSA, Ara-C, and VP 16.
    Haematology and blood transfusion, 1987, Volume: 30

    Topics: Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Child; Cytarabine; Etoposide; Female; Hum

1987
Remission of rheumatoid arthritis with the successful treatment of acute myelogenous leukemia with cytosine arabinoside, daunorubicin, and m-AMSA.
    Arthritis and rheumatism, 1987, Volume: 30, Issue:10

    Topics: Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Arthritis, Rheumatoid; Cytarabine; Daunor

1987
Pulmonary complications of cytosine-arabinoside therapy: radiographic findings.
    AJR. American journal of roentgenology, 1987, Volume: 149, Issue:1

    Topics: Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Etoposide; Humans; Leukemia,

1987
Pharmacokinetics of amsacrine in patients receiving combined chemotherapy for treatment of acute myelogenous leukemia.
    Cancer chemotherapy and pharmacology, 1985, Volume: 14, Issue:1

    Topics: Adult; Aged; Aminoacridines; Amsacrine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy

1985
Intermediate and high-dose ARA-C and m-AMSA (or daunorubicin) as remission and consolidation treatment for patients with relapsed acute leukaemia and lymphoblastic non-Hodgkin lymphoma.
    Scandinavian journal of haematology, 1985, Volume: 34, Issue:1

    Topics: Adolescent; Adult; Aminoacridines; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytara

1985
Amsacrine and etoposide induced paralytic ileus in a patient with acute myelomonocytic leukemia.
    Journal of surgical oncology, 1985, Volume: 28, Issue:3

    Topics: Aged; Aminoacridines; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Etoposide; Humans;

1985
[Treatment of acute myeloid leukemia with amsacrine and high-dose cytosine arabinoside: a phase II trial].
    Bulletin du cancer, 1985, Volume: 72, Issue:1

    Topics: Adult; Aminoacridines; Amsacrine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoc

1985
Modulation of cytosine arabinoside (ara-C) and high-dose ara-C in acute leukemia.
    Seminars in oncology, 1985, Volume: 12, Issue:2 Suppl 3

    Topics: Aminoacridines; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Drug Resistan

1985
[Experiences with HD-Ara C treatment in leukemia patients].
    Onkologie, 1985, Volume: 8, Issue:1

    Topics: Acute Disease; Aminoacridines; Amsacrine; Antineoplastic Combined Chemotherapy Protocols; Cytarabine

1985
[AMSA/etoposide (VP 16-213). A phase I/II study in refractory acute myeloid leukemia].
    Onkologie, 1985, Volume: 8, Issue:3

    Topics: Aminoacridines; Aminoglutethimide; Amsacrine; Antineoplastic Agents; Antineoplastic Combined Chemoth

1985